Post-Marketing Safety Concerns with Upadacitinib: A Disproportionality Analysis of the FDA Adverse Event Reporting system-Reference-Cited by-同舟云学术

Post-Marketing Safety Concerns with Upadacitinib: A Disproportionality Analysis of the FDA Adverse Event Reporting system

Published:2023-06-20 Issue:10 Volume:22 Page:975-984
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Wu Xiang-Ping¹²³,Lu Xi-Kui¹²³,Wang Zhen-Ting¹²³,Huang Ling¹³,Cai Ru-Wen¹²³,Yu Hui-Min¹³,Li Jing-Yang¹³,Xiao Jian¹³

Affiliation:

1. Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China

2. College of Pharmacy, Dali University, Dali, Yunnan, China

3. Department of Pharmacy, Institute for Rational and Safe Medication Practices, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China

Funder

Hunan Provincial Natural Science Foundation of 2021

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2023.2223952

Reference45 articles.

1. Thromboembolic events in Janus kinase inhibitors: A pharmacovigilance study from 2012 to 2021 based on the Food and Drug Administration's Adverse Event Reporting System

2. Potential Adverse Events Reported With the Janus Kinase Inhibitors Approved for the Treatment of Rheumatoid Arthritis Using Spontaneous Reports and Online Patient Reviews

3. The Therapeutic Landscape of Rheumatoid Arthritis: Current State and Future Directions

4. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach

5. Upadacitinib. In: LiverTox: clinical and research information on drug-induced liver injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. Aug 30, 2022.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety of tildrakizumab: a disproportionality analysis based on the FDA adverse event reporting system (FAERS) database from 2018–2023;Frontiers in Pharmacology;2024-07-10

2. Post-marketing safety concerns with abrocitinib: a real-world pharmacovigilance analysis of the FDA adverse event reporting system;Expert Opinion on Drug Safety;2024-05-17

3. Safety of Janus kinase inhibitors compared to biological DMARDs in patients with rheumatoid arthritis and renal impairment: the ANSWER cohort study;Clinical and Experimental Medicine;2024-05-10

4. Earlier onset of acute venous thromboembolism with upadacitinib compared with tofacitinib during Janus kinase inhibitor therapy;Research and Practice in Thrombosis and Haemostasis;2024-05